Zobrazeno 1 - 10
of 90
pro vyhledávání: '"D. V Kurkin"'
Autor:
A. N. Afanaseva, V. B. Saparova, I. E. Makarenko, T. A. Selmenskikh, D. V. Kurkin, A. L. Hohlov, R. V. Drai
Publikováno v:
Разработка и регистрация лекарственных средств, Vol 13, Iss 1, Pp 247-255 (2024)
Introduction. Romiplostim is an analogue of the fusion protein peptide of thrombopoietin (TPO), which increases platelet count by binding and activating the human thrombopoietin receptor (TPO-R). It is used to treat thrombocytopenia associated with c
Externí odkaz:
https://doaj.org/article/b275653dfe8748d792b2e41f4c5157b3
Autor:
V. I. Zvereva, D. R. Dzhavakhyan, V. N. Dul, V. S. Bobyleva, A. A. Markaryan, E. I. Morkovin, D. V. Kurkin, M. A. Dzhavakhyan
Publikováno v:
Фармакоэкономика, Vol 16, Iss 4, Pp 630-642 (2024)
Objective: to assess the relevance and commercial prospects of bringing to market a drug for the local treatment of infectious and inflammatory diseases of oral cavity and oropharynx.Material and methods. The objects of the study were the drug nomenc
Externí odkaz:
https://doaj.org/article/084fcde3b1af4ff490041418c33c3be4
Autor:
A. S. Ametov, I. E. Shokhin, E. A. Rogozhina, T. G. Bodrova, M. E. Nevretdinova, P. A. Bely, K. Ya. Zaslavskaya, V. S. Scherbakova, D. V. Kurkin, K. N. Koryanova, E. S. Mishchenko, E. Yu. Kesova, E. D. Kozlov, E. S. Samoshkina, D. N. Andreev, Yu. G. Kazaishvili, S. M. Noskov, L. A. Balykova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 4, Pp 324-346 (2024)
Semaglutide is a representative of analogues of the incretin hormone human glucagon-like peptide-1 (GLP-1) and is currently used in Russia for the treatment of type 2 diabetes mellitus (T2DM; in monotherapy and in combination therapy), including pati
Externí odkaz:
https://doaj.org/article/c34ff57fdc98416a8dce0a84dbcfc85b
Autor:
D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, A. V. Zaborovsky, I. E. Makarenko, R. V. Drai, A. G. Solodovnikov, V. I. Petrov, K. N. Koryanova, N. A. Lycheva, S. A. Voskresensky, A. V. Strygin, Yu. A. Kolosov, Yu. V. Gorbunova, O. V. Ivanova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 5, Pp 384-398 (2024)
The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.Materials and methods. Th
Externí odkaz:
https://doaj.org/article/2dc8114950e748bbbd40243f3b14fe6b
Autor:
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, V. I. Petrov, A. V. Strygin, K. N. Koryanova, Yu. V. Gorbunova, Yu. A. Kolosov, O. V. Ivanova, E. V. Pavlova, M. A. Dzhavakhyan, A. V. Zaborovsky, V. B. Saparova, I. E. Makarenko, R. I. Drai, A. N. Chumachenko
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 4, Pp 347-380 (2024)
Modern approaches to the treatment of type 2 diabetes mellitus (T2DM) are aimed not only at glycemic control, but also at reducing cardiovascular risks. The increasing prevalence of the disease and the need for effective treatment options highlight t
Externí odkaz:
https://doaj.org/article/95f6d86f77b4438484e0b9ff432b4ee0
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 4, Pp 280-290 (2024)
Therapeutic drug monitoring (TDM) is used to increase the individualization of pharmacotherapy, especially in patient groups with a high interindividual variability in pharmacokinetic (PK) parameters. One of these groups of patients is newborn childr
Externí odkaz:
https://doaj.org/article/ca68963d8b8f45b89606e67601361cde
Autor:
A. S. Ametov, I. E. Shokhin, E. A. Rogozhina, T. G. Bodrova, M. E. Nevretdinova, P. A. Bely, K. Ya. Zaslavskaya, D. V. Kurkin, K. N. Koryanova, E. S. Mishchenko, S. M. Noskov
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 3, Pp 255-276 (2023)
Liraglutide is one of the analogues of the incretin hormone human glucagon-like peptide-1 (GLP-1) and is currently a priority treatment for diseases such as type 2 diabetes mellitus (mono- and combination therapy), obesity and overweight in the prese
Externí odkaz:
https://doaj.org/article/2594ff78904340c69eb6d062f929ba86
Autor:
D. V. Kurkin, E. I. Morkovin, D. A. Bakulin, Yu. V. Gorbunova, Yu. A. Kolosov, M. A. Dzhavakhyan, I. E. Makarenko, R. V. Drai, A. V. Zaborovsky, O. V. Shatalova, A. V. Strygin, V. I. Petrov, A. P. Pleten, A. A. Prokopov, T. Yu. Tatarenko-Kozmina
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 3, Pp 193-210 (2023)
The aim of the work is to conduct a review of medications approved by the FDA in 2022.Materials and methods. In searching for the materials to write this review article, bibliographic databases including PubMed, Google Scholar and e-library.ru were u
Externí odkaz:
https://doaj.org/article/8583ca5a7d4043de9ab1b0dd5ccb0858
Autor:
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, Yu. V. Gorbunova, A. V. Strygin, T. M. Andriashvili, A. A. Sokolova, N. S. Bolokhov, V. E. Pustynnikov, E. A. Fomichev, A. V. Baskova, S. S. Polodyants, A. V. Kasparova
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 2, Pp 104-113 (2023)
The aim of the study was to evaluate a cerebroprotective activity of the sitagliptin and aminoguanidine combination in rats with an acute and chronic cerebral circulation insufficiency, as well as with a traumatic brain injury.Materials and methods.
Externí odkaz:
https://doaj.org/article/91ea2398488e41cb8546951fb823d06b
Autor:
D. V. Kurkin, D. A. Bakulin, E. I. Morkovin, A. V. Strygin, Yu. V. Gorbunova, E. V. Volotova, I. E. Makarenko, V. B. Saparova, R. V. Drai, V. I. Petrov
Publikováno v:
Фармация и фармакология (Пятигорск), Vol 11, Iss 1, Pp 19-47 (2023)
Modern requirements for the treatment of type 2 diabetes mellitus (DM2) include not only achieving a glycemic control, but also reducing the risk of developing cardiovascular complications. Dipeptidyl peptidase 4 (DPP-4) inhibitors are inferior in th
Externí odkaz:
https://doaj.org/article/f0fe50a3b67f4dd0bc0505b700df9935